Mortality and Severity in COVID-19 Patients on ACEIs & ARBs - A Meta-Regression Analysis

Romil Singh, Sawai Singh Rathore, Hira Khan, Abhishek Bhurwal, Mack Sheraton, Prithwish Ghosh, Sohini Anand, Janaki Makadia, FNU Ayesha, Kiran S. Mahapure, Ishita Mehra, Aysun Tekin, Rahul Kashyap, Vikas Bansal
doi: https://doi.org/10.1101/2021.03.14.21253557

Abstract

Purpose The primary objective of this review is to examine studies reporting association of mortality in COVID-19 patients with whether they were on Angiotensin-converting-enzyme inhibitors (ACEIs) and Angiotensin II receptor blockers (ARBs). A secondary objective is to similarly access associations with higher severity of the disease in COVID-19 patients.

Materials and Methods We searched multiple COVID-19 databases (WHO, CDC, LIT-COVID) for randomized trials and longitudinal studies from all over the world reporting mortality and severity published before January 18th, 2021. Meta-analyses were performed using 53 studies for mortality outcome and 43 for the severity outcome. Mantel-Haenszel odds ratios were generated to describe overall effect size using random effect models. To account for between study results variations, multivariate meta-Regression was performed with preselected covariates using maximum likelihood method for both the mortality and severity models.

Result Our findings showed that the use of ACEIs/ARBs did not significantly influence either mortality (OR=1.16 95% CI 0.94 to 1.44, p= 0.15, I2 = 93.2%) or severity (OR=1.18, 95% CI 0.94 to 1.48 p= 0.15, I2 = 91.1%) in comparison to not being on ACEIs/ARBs in COVID-19 positive patients. Multivariate meta-regression for the mortality model demonstrated that 36% of between study variations could be explained by differences in age, gender, and proportion of heart diseases in the study samples. Multivariate meta-regression for the severity model demonstrated that 8% of between study variations could be explained by differences in age, proportion of diabetes, heart disease and study country in the study samples.

Conclusion We found no association of mortality or severity in COVID-19 patients taking ACEIs/ARBs.

Introduction

SARS-CoV-2 originated in Wuhan, China, in December 2019 and has spread to every major country in the world and was subsequently declared a pandemic on March 11, 20201. As of March 10th, 2021, there are 117,997,454 positive patients worldwide; and 2,619,379 of these patients were reported to be deceased because of SARS-CoV-22. The case fatality rate of SARS-CoV-2 in the U.S. is 1.05 per 1000 population as per COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University2. However, the role of different medications and comorbidities has been elicited in recent articles.

The SARS-CoV-2 disease varies from mild to fulminant in reference to several risk variables contributing to a poor prognosis3-5. While the virus significantly impacts the respiratory tract, other metabolic systems have been involved in numerous case studies and systematic reviews6-14. Thorough awareness of the risks, pathogenesis, and predisposing factors together with the important aspects in the diagnosis is of paramount importance in order to direct decision-making for acute care and mitigate mortality of COVID-1915-19.

Severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 uses the receptor angiotensin-converting enzyme (ACE) 2 for entry into target cells, and it was reported that both Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) could increase the mRNA expression of cardiac ACE2 receptors20. However, controversy about the novel use of Renin-angiotensin system (RAS) blockers has been raised amid this SARS-CoV-2 pandemic.

The explanation behind this controversy arises from the very fact that it shares the target receptor site with ACEIs and ARBs, which can cause the upregulation of ACE2 receptors21. ACE2 is additionally the notable cellular surface receptor and a necessary entry point for SARS-CoV-2 into the target cell22. As cardiovascular diseases and their therapy affects ACE2 levels, it plays an integral part in consideration of infectivity and outcomes of SARS-CoV-2. It needs to be imperatively determined whether treatment or disease-induced up-regulation of ACE2 impacts the trajectory of SARS-CoV-220. ACEIs/ARBs are often used to treat hypertension, which is the most common comorbidity associated with SARS-CoV-223. As there is no clinical evidence, major international cardiology societies recommend continuing the use of ACEIs and ARBs in SARS-CoV-2 patients24.

Due to limited literature on the influence of ACE inhibitors and ARBs in COVID-19 patients, we systematically reviewed the relevant medical literature. We performed a meta-analysis and meta-regression to investigate the association of ACEIs and ARBs used in COVID-19 and its effect on the mortality rate and severity of COVID-19.

Methodology

We have presented this review according to the Preferred Systematic Reviews and Meta-Analysis Reporting Items guidelines for documenting analysis25.

Search strategy

We searched WHO COVID-19 Global research database, Lit-COVID26, CDC Database of COVID-19 Research including PubMed, Embase, Scopus, Science Web, and Cochrane Central Controlled Trials Registry. The MedRxiv and SSNR preprint servers were also scanned. The searches were performed from December 2019 and revised till January 18th, 2021. The search approach and design can be found in Figure-1. Studies from all around the world were included, there were no language barriers. In an attempt to discover further eligible studies, we manually searched the reference lists of the included studies and the relevant literature. We also scanned the clinicaltrials.gov registry for completed, as well as in-progress randomized controlled trials (RCTs).

Figure 1:
Figure 1: PRISMA flow diagram

Eligibility criteria

Criteria of eligibility: We included observational studies assessing the association between the use of the ACEI or ARB and at least one functional endpoint in COVID-19 positive patients diagnosed by RT-PCR. Case reports, narrative reviews, commentaries, and abstracts were excluded. The cases included Covid-19 positive patients on ACEI or ARB and the controls included the remaining COVID-19 positive patients.

Study Selection

Three authors (RS, SSR, and HK) downloaded all articles from electronic search to EndNote X927, as well as duplicates were eliminated. Titles and abstracts were autonomously evaluated by authors (AT, FA, HK, JM, KM, PG, RS, SA, and SSR) to identify and assess key articles. Further, authors (FA, HK, JM, KM, PG, RS, SA, and SSR) independently reviewed the entire manuscript and registered justification for the exclusion. Any discrepancies were addressed by arbitration.

Outcome

All-cause mortality in the COVID-19 affected patient was the chief outcome, while severity of disease was the secondary outcome.

Data Extraction

The authors (FA, HK, JM, KM, PG, RS, SA, and SSR), using a standardized data extraction method, extracted information from each survey independently; any conflict was resolved by consensus. The following dataset points were extracted: First author name, cases on ACEI-ARB, total COVID positive patients, country of study, study design, hypertension proportion, diabetes proportion, heart disease proportion, eligibility criteria, Median age, gender (female sex proportion), comorbidities, use of ACEIs or ARBs and primary and secondary outcomes (mortality and severity). Unadjusted and adjusted impact measurements were also extracted where appropriate.

Statistical analysis

The meta-analysis specifically included longitudinal and cross-sectional studies comparing the effects of COVID-19 in subjects who were on ACEIs/ARBs at the time of infection with those who were not. Meta-analysis was performed first for studies reporting mortality of patients in both groups, followed by that for studies reporting severity of disease assuming independence of results for studies that reported both. Due to anticipated heterogeneity, summary statistics were calculated using a random-effects model. This model accounts for variability between studies as well as within studies. In all cases, meta-analyses were performed using the Mantel-Haenszel method for dichotomous data to estimate pooled odds ratios (OR) and statistical heterogeneity was assessed using Q value and I2 statistics. The meta-analysis and meta-regression was done with the Comprehensive Meta-Analysis software package (Biostat, Englewood, NJ, USA)28. We included the region of study in meta-regression model to find out whether Asian studies, which were dated earlier than studies from the rest of the world, contributed disproportionately to the significance of results. This helped rule out location and pipeline biases.

To explore differences between studies that might be expected to influence the effect size, we performed random effects (maximum likelihood method) univariate and multivariate meta-regression analyses. The potential sources of variability defined were median age of study sample, proportion of subjects of female sex, proportion of diabetics and proportion with heart diseases. Covariates were selected for further modeling if they significantly (P <0 .05) modified the association between mortality or severity in the COVID19 infected and treatment with ACEIs/ARBs. Two models were created, one for mortality and the other for severity of disease as outcomes. Subsequently, preselected covariates were included in a manual backward and stepwise multiple meta-regression analysis with P = 0.05 as a cutoff point for removal. P <0 .05 (P < 0.10 for heterogeneity) was considered statistically significant. All meta-analysis and meta-regression tests were 2-tailed.

Results

The initial library search identified potentially relevant citations from WHO Global Research Database, CDC COVID-19 Research Articles Downloadable Database, and LitCovid PubMed database comprised of 393,597 articles. Subsequently, 393,285 articles were removed because of unclear evidence and non-relevance to the objective of the manuscript. Out of the remaining 312 articles, a total of 244 articles consisting of case reports, abstracts, letter to editor, and narrative reviews were excluded. Thus, 68 studies29-96 were included in their entirety as shown in Table 1. The PRISMA flow chart is shown in Figure 1.

View this table:
Table 1: Study characteristics

Study characteristics of included studies

A total of fifty three studies29-81 were included for meta-analysis for the primary outcome i.e. mortality. In total, these consisted of 112,468 subjects with 16,363 mortality events. Median age for all studies was 64.9 (60.9-67.2) with average 47.3% females (Table 1). Of the comorbidities considered, 25.4% were diabetics, 16.6% had heart diseases overall. Similarly, a total of forty three studies29,31,33,36-38,41,43,45-47,49,53,55-57,59-61,64-66,69,73,74,76,77,79,82-96 were included for meta-analysis for the secondary outcome i.e. severity of disease. These had a combined sample size of 37,914 with 6,985 patients reaching the endpoint of high disease severity. The median age was 65.2 (60.8-68.7) and 46.2% were females, 25.6% were diabetics, 17.1% had heart diseases overall in this cohort (Table 1).

Meta-analysis for mortality outcome

Meta-analysis findings showed that being on ACEIs/ARBs did not have an association with mortality from COVID 19 infections compared to not being on ACEIs/ARBs (OR=1.17, 95% CI 0.94 to 1.45, p= 0.15). Heterogeneity was very high with I2 = 93.2% (Figure 2).

Figure 2:
Figure 2: Forest plot for association of ACE/ARBs on mortality in COVID19 patients

Meta-analysis for severity outcome

Findings from the meta-analysis showed that being on ACEI/ARBs did not have an association with severity from COVID 19 infections compared to not being on ACEIs/ARBs (OR=1.18, 95% CI 0.94 to 1.48, p= 0.15). Heterogeneity was very high with I2 = 91.1% (Figure 3).

Figure 3:
Figure 3: Forest plot for association of ACE/ARBs on severity in COVID19 patients

Multivariate meta-regression model for mortality outcome

Multivariate meta-regression performed to explain variations in association between mortality and being on ACEIs/ARBs revealed; age, female gender, proportion of heart diseases in included studies covariates to be significant together and explained R2=36% of the between study heterogeneity in mortality. Figure 4 shows the resulting equation and individual covariate effect graphs.

Figure 4:
Figure 4: Meta-regression results for covariates significantly influencing mortality (R2=36)

Multivariate meta-regression model for severity outcome

Multivariate meta-regression performed to explain variations in association between severity and being on ACEIs/ARBs revealed age, proportion with diabetes, heart disease and country of studies covariates to be significant together. These covariates together explained R2= 8% of the study heterogeneity in severity. Figure 5 shows the resulting equation and individual covariate effect graphs.

Figure 5:
Figure 5: Meta-regression results for covariates significantly influencing severity (R2=8%)

Risk of bias assessment

The Newcastle-Ottawa (NOS) scale97 was used for measuring the risk of bias in cohort and case-control studies (Table 2A & 2B). The following classes were rated per study: low bias risk (9 points), moderate bias risk (5-7 points), and high bias risk (0-4 items). For a cross-sectional study, we used the modified version of NOS, assigning the study in the following groups: Low risk of bias (8-10), moderate risk (5-7), high risk of bias (0-4). Three reviewers (RS, SSR, and PG) evaluated the likelihood of bias independently, and any conflict was resolved by consensus.

View this table:
Table 2: New Castle Ottawa Scale

Publication Bias

Visual inspection of the standard error plots for the mortality analysis (Figure 6A) suggests symmetry without an underrepresentation of studies of any precision but indicated underrepresentation of studies with smaller effect sizes. Classic fail-safe N analysis computed taking alpha at 0.05 put the number of missing studies at 5. Corroborating inspection findings, in Egger’s regression test the null hypothesis of no small study effects was not rejected at P<0.05 (estimated bias coefficient = −0.28 ± 0.76 SE).

Figure 6:
Figure 6: Funnel plots for publication bias of Mortality (A) and Severity (B) models:

Similarly, visual inspection of the standard error plots for the severity analysis also (Figure 6B) suggest symmetry without an underrepresentation of studies of any precision but indicated underrepresentation of studies with smaller effect sizes. Classic fail-safe N analysis computed taking alpha at 0.05 put the number of missing studies at 8. However, in Egger’s regression test the null hypothesis of no small study effects was rejected at P<0.05 (estimated bias coefficient = −1.14 ± 0.81SE).

Discussion

Based on our meta-analysis consisting of cross-sectional, case-control, and cohort studies, the use of ACEIs and ARBs was neither associated with increased all-cause mortality nor with increased severity of disease progression in COVID-19 patients. Multivariate meta-regression for the mortality model demonstrated that 36% of study variations could be explained by differences in age, female gender, proportion of heart diseases in the study samples. Multivariate meta-regression for the severity model demonstrated that 8% of study variations could be explained by differences in age, proportion of diabetes, heart diseases and country of studies in the study samples. This finding is valuable as association between ACEIs and ARBs use and outcome in COVID-19 patients has been inconclusive so far. To our knowledge, this is the first meta-regression, and the largest meta-analysis to evaluate the role of ACEIs/ARBs as an antihypertensive regimen in hospitalized patients with COVID-19.

The effect of ACEIs/ARBs use on COVID-19 patients has been a controversial topic since the beginning of this pandemic, and some studies even have interposed a risk of taking ACEIs/ARBs using data from previous coronavirus outbreaks and preclinical studies98. Previously published systematic reviews, suggested a lower mortality (25-43%) in patients with hypertension hospitalized for COVID1999-101. Furthermore, a large-scale retrospective study demonstrated that in-hospital use of ACEIs/ARBs was associated with a lower risk of 28-day death among hospitalized patients with COVID-19 and coexisting hypertension (adjusted HR 0.32, 95% CI 0.15 to 0.66)78. These data suggested that patients with hypertension might obtain benefits from taking ACEIs/ARBs compared with the non-ACEIs/ARBs in the setting of COVID-19 and support the hypothesis that a drug that diminishes angiotensin-2 activity, such as ACEIs and/or ARBs, can reduce the deadliness of inflammation associated injury in COVID-19. Our result trends in contraindicating the above study results but did not reach statistical significance. Our meta-analysis suggests that the use of ACEIs/ARBs neither increase nor decrease mortality in COVID-19 patients (figure 2). In addition to what is reported in published studies, our systematic review added the most recent studies, and had the largest sample size (53 studies, 112,468 patients).

The main strength of our analysis is the large sample size along with a robust and comprehensive search. The large sample size enables the precision and reliability of risk estimates. Additionally, further meta-regression was performed to adjust for confounding factors. However, despite all the strengths, there are still certain limitations. The major limitation of the meta-regression is the presence of unknown confounders. Multiple previous studies have reported that gender, age, smoking history, and presence of diabetes influence COVID-19 results. Even though these confounders are reported in most of the included studies, further studies focusing on the adjustment of confounders are necessary. We included studies from the medRxiv.org databases and other preprint database which did not go through peer review at that time. We considered this as a limitation, as peer reviewers could catch more deficiencies in reporting methods and other details. However, it was anticipated that majority of these studies would be peer-reviewed. Third, the use of ACE/ARB has been via medical record review which could be less reliable. Finally, the definition of COVID-19 severity and outcomes were not uniform among the included studies.

In conclusion, meta-regression analysis suggest that the use of ACEIs/ARBs in patients with COVID-19 is not associated with increased mortality or increased severity. However, multivariate meta-regression model for mortality indicated that 36% study variation could be due to differences in age, female gender, proportion of heart diseases in the study samples. Similarly, multivariate meta-regression for the severity model exhibited that 8% of study variations could be explained by differences in age, proportion of diabetes, heart disease and country of studies in the study samples. Larger observational studies102-105 and clinical trials are warranted to confirm these findings. Providers should continue to manage patient hypertension as per current treatment guidelines106,107 and clinical judgement.

Data Availability

We performed a meta-analysis from already published literature (preprint and peer-reviewed).

Footnotes

  • Conflict of Interest Statement: None of the authors have any conflict of interest to declare.

References

  1. 1.↵
    Shah A, Kashyap R, Tosh P, Sampathkumar P, O’Horo JC. Guide to Understanding the 2019 Novel Coronavirus. Mayo Clin Proc. 2020;95(4):646–652.
    OpenUrl
  2. 2.↵
    Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–534.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Domecq JP, Lal A, Sheldrick CR, et al. Outcomes of Patients With Coronavirus Disease 2019 Receiving Organ Support Therapies: The International Viral Infection and Respiratory Illness Universal Study Registry. Critical Care Medicine. 9000;Online First.
  4. 4.
    Bansal V, Singh R, Bhurwal A, Rathore S, Kashyap R. 117: Obesity Is a Risk Factor for Increased COVID-19 Severity: A Systemic Review and Meta-Regression. Critical Care Medicine. 2021;49(1):43.
    OpenUrl
  5. 5.↵
    Kirkup C, Pawlowski C, Puranik A, et al. Healthcare disparities among anticoagulation therapies for severe COVID-19 patients in the multi-site VIRUS registry. J Med Virol. 2021.
  6. 6.↵
    Rathore SS, Rojas GA, Sondhi M, et al. Myocarditis associated with Covid-19 disease: a systematic review of published Case reports and Case series. Authorea. 2021.
  7. 7.
    Sheraton M, Deo N, Kashyap R, Surani S. A Review of Neurological Complications of COVID-19. Cureus. 2020;12(5).
  8. 8.
    Khan H, Sabzposh H, Deshpande S, Kashyap R. Pregnancy during COVID-19 pandemic– Maternal and neonatal outcomes: A concise review. International Journal of Academic Medicine. 2020;6(4):287.
    OpenUrl
  9. 9.
    Shah K, Mann S, Singh R, Bangar R, Kulkarni R. Impact of COVID-19 on the Mental Health of Children and Adolescents. Cureus. 2020;12(8).
  10. 10.
    Sheraton M, Deo N, Dutt T, Surani S, Hall-Flavin D, Kashyap R. Psychological effects of the COVID 19 pandemic on healthcare workers globally: A systematic review. Psychiatry research. 2020;292:113360.
    OpenUrl
  11. 11.
    Singh R, Kashyap R, Hutton A, Sharma M, Surani S. A Review of Cardiac Complications in Coronavirus Disease 2019. Cureus. 2020;12(5).
  12. 12.
    Bhalala U, Gist K, Tripathi S, et al. 145: Pediatric COVID-19: A Report From Viral Infection and Respiratory Illness Universal Study (VIRUS). Critical Care Medicine. 2021;49(1):58.
    OpenUrl
  13. 13.
    Tripathi S, Gist K, Chiotos K, et al. 61: Risk Factors for Severe COVID-19 Illness in Children: Analysis of the VIRUS: COVID-19 Registry. Critical Care Medicine. 2021;49(1):32.
    OpenUrl
  14. 14.↵
    Menon T, Sharma R, Earthineni G, et al. Association of Gastrointestinal System With Severity and Mortality of COVID-19: A Systematic Review and Meta-Analysis. Cureus. 2021;13(2).
  15. 15.↵
    Mehra I, Mahapure K, Armaly P, et al. 146: Controversial Role of Corticosteroids on Mortality in COVID-19: Systematic Review and Meta-Analysis. Critical Care Medicine. 2021;49(1):58.
    OpenUrl
  16. 16.
    RSingh Ls, I Mehra, R Kashyap, S Surani. Novel and Controversial Therapies in COVID-19. The Open Respiratory Medicine Journal. 2020;14.
  17. 17.
    Bansal V, Mahapure K, Bhurwal A, et al. Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-analysis. Frontiers in Medicine. 2020;7:1124.
    OpenUrl
  18. 18.
    Jain R, Javeri Y, Nasa P, et al. Consensus Statement for Pharmacological Management of Coronavirus Disease 2019 (COVID-19): A Pragmatic Approach. Asploro Journal of Biomedical and Clinical Case Reports. 2020;3(3):241.
    OpenUrl
  19. 19.↵
    Kirkup C, Pawlowski C, Puranik A, et al. Healthcare disparities among anticoagulation therapies for severe COVID-19 patients in the multi-site VIRUS registry. medRxiv. 2020.
  20. 20.↵
    Sommerstein R, Kochen MM, Messerli FH, Grani C. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? J Am Heart Assoc. 2020;9(7):e016509.
    OpenUrlCrossRefPubMed
  21. 21.↵
    Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–269.
    OpenUrlCrossRefPubMed
  22. 22.↵
    Tikellis C, Thomas MC. Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. Int J Pept. 2012;2012:256294.
    OpenUrlCrossRefPubMed
  23. 23.↵
    Kanwal A, Agarwala A, Martin LW. COVID-19 and Hypertension: What We Know and Don’t Know. American College of Cardiology. 2020;6.
  24. 24.↵
    Bavishi C, Maddox TM, Messerli FH. Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers. JAMA Cardiol. 2020;5(7):745–747.
    OpenUrl
  25. 25.↵
    Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    Chen Q, Allot A, Lu Z. LitCovid: an open database of COVID-19 literature. Nucleic Acids Res. 2021;49(D1):D1534–D1540.
    OpenUrl
  27. 27.↵
    Hupe M. EndNote X9. Journal of Electronic Resources in Medical Libraries. 2019;16(3-4):117–119.
    OpenUrl
  28. 28.↵
    Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-Analysis Version 3. Biostat, Englewood, NJ 2013. https://www.meta-analysis.com/index.php?cart=BBFA4702757. xPublished 2013. Updated 03/11/2021. Accessed 03/11/2021.
  29. 29.↵
    Bae DJ, Tehrani DM, Rabadia SV, et al. Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use Among Outpatients Diagnosed With COVID-19. Am J Cardiol. 2020;132:150–157.
    OpenUrl
  30. 30.
    Baker KF, Hanrath AT, Schim van der Loeff I, et al. COVID-19 Management in a UK NHS Foundation Trust with a High Consequence Infectious Diseases Centre: A Retrospective Analysis. Med Sci (Basel). 2021;9(1):2020.2005.2014.20100834.
  31. 31.↵
    Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M. COVID-19 infection in kidney transplant recipients. Kidney Int. 2020;97(6):1076–1082.
    OpenUrlCrossRefPubMed
  32. 32.
    Bauer AZ, Gore R, Sama SR, et al. Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study. The Journal of Clinical Hypertension. 2021;23(1):21–27.
    OpenUrl
  33. 33.↵
    Bean D, Kraljevic Z, Searle T, et al. ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS-COVID19 infection in a multi-site UK acute Hospital Trust. medRxiv. 2020:2020.2004.2007.20056788.
  34. 34.
    Benelli G, Buscarini E, Canetta C, et al. SARS-COV-2 comorbidity network and outcome in hospitalized patients in Crema, Italy. medRxiv. 2020:2020.2004.2014.20053090.
  35. 35.
    Braude P, Carter B, Short R, et al. The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19. Int J Cardiol Heart Vasc. 2020;31:100660.
    OpenUrl
  36. 36.↵
    Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63(8):1500–1515.
    OpenUrlCrossRefPubMed
  37. 37.
    Cetinkal G, Balaban Kocas B, Ser OS, et al. The Association between Chronic Use of Renin–Angiotensin-Aldosterone System Blockers and in-Hospital Adverse Events among COVID-19 Patients with Hypertension. Med Bull Sisli Etfal Hosp. 2020;54(4):399–404.
    OpenUrl
  38. 38.↵
    Chaudhri I, Koraishy FM, Bolotova O, et al. Outcomes Associated with the Use of Renin-Angiotensin-Aldosterone System Blockade in Hospitalized Patients with SARS-CoV-2 Infection. Kidney360. 2020;1(8):801–809.
    OpenUrlAbstract/FREE Full Text
  39. 39.
    Chen M, Fan Y, Wu X, et al. Clinical Characteristics And Risk Factors For Fatal Outcome in Patients With 2019-Coronavirus Infected Disease (COVID-19) in Wuhan, China. SSRN Electronic Journal. t2020.
  40. 40.
    Chen Y, Yang D, Cheng B, et al. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. Diabetes Care. 2020;43(7):1399–1407.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    Choi HK, Koo H-J, Seok H, et al. ARB/ACEI use and severe COVID-19: a nationwide case-control study. medRxiv. 2020:2020.2006.2012.20129916.
  42. 42.
    Conversano A, Melillo F, Napolano A, et al. Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia. Hypertension. 2020;76(2):e10–e12.
    OpenUrl
  43. 43.↵
    Covino M, De Matteis G, Burzo ML, et al. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID-19. Internal Medicine Journal. 2020;50(12):1483–1491.
    OpenUrl
  44. 44.
    Desai A, Voza G, Paiardi S, et al. The role of anti-hypertensive treatment, comorbidities and early introduction of LMWH in the setting of COVID-19: A retrospective, observational study in Northern Italy. International Journal of Cardiology. 2021;324:249–254.
    OpenUrl
  45. 45.↵
    Felice C, Nardin C, Di Tanna GL, et al. Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives. Am J Hypertens. 2020.
  46. 46.
    Fosbol EL, Butt JH, Ostergaard L, et al. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. JAMA. 2020;324(2):168–177.
    OpenUrlCrossRefPubMed
  47. 47.↵
    Genet B, Vidal J-S, Cohen A, et al. COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients. Journal of the American Medical Directors Association. 2020;21(11):1539–1545.
    OpenUrl
  48. 48.
    Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–818.
    OpenUrl
  49. 49.↵
    Hakeam HA, Alsemari M, Al Duhailib Z, et al. Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study. Journal of Cardiovascular Pharmacology and Therapeutics. 2020:1074248420976279.
  50. 50.
    Huang Z, Cao J, Yao Y, et al. The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension. Ann Transl Med. 2020;8(7):430.
    OpenUrl
  51. 51.
    Ip A, Parikh K, Parrillo JE, et al. Hypertension and Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. medRxiv. 2020:2020.2004.2024.20077388.
  52. 52.
    Jung S-Y, Choi JC, You S-H, Kim W-Y. Association of Renin-angiotensin-aldosterone System Inhibitors With Coronavirus Disease 2019 (COVID-19)-Related Outcomes in Korea: A Nationwide Population-based Cohort Study. Clinical Infectious Diseases. 2020.
  53. 53.↵
    Kim JH, Baek Y-H, Lee H, Choe YJ, Shin HJ, Shin J-Y. Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study. medRxiv. 2020:2020.2007.2029.20164822.
  54. 54.
    Kim L, Garg S, O’Halloran A, et al. Interim Analysis of Risk Factors for Severe Outcomes among a Cohort of Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). medRxiv. 2020:2020.2005.2018.20103390.
  55. 55.↵
    Lafaurie M, Martin-Blondel G, Delobel P, Charpentier S, Sommet A, Moulis G. Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: results of the ACE-CoV study. Fundamental & Clinical Pharmacology. 2021;35(1):194–203.
    OpenUrl
  56. 56.
    Lahens A, Mullaert J, Gressens S, et al. Association between renin–angiotensin– aldosterone system blockers and outcome in coronavirus disease 2019: analysing in-hospital exposure generates a biased seemingly protective effect of treatment. Journal of Hypertension. 2021;39(2):367–375.
    OpenUrl
  57. 57.↵
    Lam KW, Chow KW, Vo J, et al. Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome. The Journal of Infectious Diseases. 2020;222(8):1256–1264.
    OpenUrlCrossRef
  58. 58.
    Lee H-Y, Ahn J, Kang CK, et al. Association of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on COVID-19-Related Outcome. SSRN Electronic Journal. 2020.
  59. 59.↵
    Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol. 2020;5(7):825–830.
    OpenUrl
  60. 60.
    Lim J-H, Cho J-H, Jeon Y, et al. Adverse impact of renin–angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study. Scientific Reports. 2020;10(1):20250.
    OpenUrl
  61. 61.↵
    Liu X, Liu Y, Chen K, et al. Efficacy of ACEIs/ARBs vs CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study. Journal of Medical Virology. 2021;93(2):854–862.
    OpenUrl
  62. 62.
    Lopez-Otero D, Lopez-Pais J, Cacho-Antonio CE, et al. Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry. Rev Esp Cardiol (Engl Ed). 2020.
  63. 63.
    Mehta N, Kalra A, Nowacki AS, et al. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(9):1020–1026.
    OpenUrl
  64. 64.↵
    Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757–760.
    OpenUrl
  65. 65.
    Oussalah A, Gleye S, Clerc Urmes I, et al. Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France. Clinical Infectious Diseases. 2020;71(9):2447–2456.
    OpenUrl
  66. 66.↵
    Peng YD, Meng K, Guan HQ, et al. [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48(6):450–455.
    OpenUrl
  67. 67.
    Rentsch CT, Kidwai-Khan F, Tate JP, et al. Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54-75 Years. medRxiv. 2020:2020.2004.2009.20059964.
  68. 68.
    Rezel-Potts E, Douiri A, Chowienczyk PJ, Gulliford MC. Antihypertensive Medications and COVID-19 Diagnosis and Mortality: Population-based Case-Control Analysis in the United Kingdom. medRxiv. 2020:2020.2009.2025.20201731.
  69. 69.↵
    Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052–2059.
    OpenUrlCrossRefPubMed
  70. 70.
    Rodilla E, Saura A, Jiménez I, et al. Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19. Journal of Clinical Medicine. 2020;9(10).
  71. 71.
    Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S. Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19. JAMA Network Open. 2020;3(12):e2029058–e2029058.
    OpenUrl
  72. 72.
    Rossi GP, Marino M, Formisano D, Venturelli F, Vicentini M, Grilli R. Characteristics and outcomes of a cohort of COVID-19 patients in the Province of Reggio Emilia, Italy. PLoS One. 2020;15(8):e0238281.
    OpenUrlPubMed
  73. 73.↵
    Soleimani A, Kazemian S, Karbalai Saleh S, et al. Effects of Angiotensin Receptor Blockers (ARBs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected COVID-19. American Journal of Hypertension. 2020;33(12):1102–1111.
    OpenUrlCrossRef
  74. 74.↵
    Tan N-D, Qiu Y, Xing X-B, Ghosh S, Chen M-H, Mao R. Associations Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality Among Patients With COVID-19. Gastroenterology. 2020;159(3):1170-1172.e1171.
    OpenUrl
  75. 75.
    Wang Y, Lu X, Li Y, et al. Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19. Am J Respir Crit Care Med. 2020;201(11):1430–1434.
    OpenUrlCrossRefPubMed
  76. 76.↵
    Yang G, Tan Z, Zhou L, et al. Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients With Hypertension. medRxiv. 2020:2020.2003.2031.20038935.
  77. 77.↵
    Zeng Z, Sha T, Zhang Y, et al. Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study. medRxiv. 2020:2020.2004.2006.20054825.
  78. 78.↵
    Zhang P, Zhu L, Cai J, et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circulation Research. 2020;126(12):1671–1681.
    OpenUrlPubMed
  79. 79.↵
    Zhong Y, Zhao L, Wu G, et al. Impact of renin–angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study. Journal of International Medical Research. 2020;48(12):0300060520979151.
    OpenUrl
  80. 80.
    Zhou F, Liu Y-M, Xie J, et al. Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality. Hypertension. 2020;76(2):e15–e17.
    OpenUrlCrossRef
  81. 81.↵
    Zhou X, Zhu J, Xu T. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin–angiotensin system inhibitors. Clinical and Experimental Hypertension. 2020;42(7):656–660.
    OpenUrl
  82. 82.↵
    Ashraf MA, Shokouhi N, Shirali E, et al. COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes. medRxiv. 2020:2020.2004.2020.20072421.
  83. 83.
    Bravi F, Flacco ME, Carradori T, et al. Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens. PLoS One. 2020;15(6):e0235248.
    OpenUrlPubMed
  84. 84.
    De Spiegeleer A, Bronselaer A, Teo JT, et al. The effects of ARBs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents. medRxiv. 2020:2020.2005.2011.20096347.
  85. 85.
    Feng Y, Ling Y, Bai T, et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am J Respir Crit Care Med. 2020;201(11):1380–1388.
    OpenUrlCrossRefPubMed
  86. 86.
    Feng Z, Li J, Yao S, et al. The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis. medRxiv. 2020:2020.2004.2008.20057539.
  87. 87.
    Golpe R, Pérez-de-Llano LA, Dacal D, Guerrero-Sande H, Pombo-Vide B, Ventura-Valcárcel P. Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors. Medicina Clínica. 2020.
  88. 88.
    Güner R, Hasanoglu I, Kayaaslan B, et al. COVID-19 experience of the major pandemic response center in the capital: Results of the pandemic’s first month in Turkey. Turk J Med Sci. 2020.
  89. 89.
    Jurado A, Martin MC, Abad-Molina C, et al. COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study. Immun Ageing. 2020;17:22.
    OpenUrl
  90. 90.
    Liu Y, Huang F, Xu J, et al. Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. medRxiv. 2020:2020.2003.2020.20039586.
  91. 91.
    Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19. New England Journal of Medicine. 2020;382(25):2431–2440.
    OpenUrlCrossRefPubMed
  92. 92.
    Reynolds HR, Adhikari S, Pulgarin C, et al. Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19. New England Journal of Medicine. 2020;382(25):2441–2448.
    OpenUrlCrossRefPubMed
  93. 93.
    Rhee SY, Lee J, Nam H, Kyoung D-S, Kim DJ. Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19. medRxiv. 2020:2020.2005.2020.20108555.
  94. 94.
    Yan HD, Valdes AM, Vijay A, et al. Role of Drugs Used for Chronic Disease Management on Susceptibility and Severity of COVID-19: A Large Case-Control Study. Clin Pharmacol Ther. 2020;108(6):1185–1194.
    OpenUrlPubMed
  95. 95.
    Anzola GP, Bartolaminelli C, Gregorini GA, et al. Neither ACEIs nor ARBs are associated with respiratory distress or mortality in COVID-19 results of a prospective study on a hospital-based cohort. Intern Emerg Med. 2020;15(8):1477–1484.
    OpenUrl
  96. 96.↵
    Huh K, Ji W, Kang M, et al. Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea. Int J Infect Dis. 2020;104:7–14.
    OpenUrl
  97. 97.↵
    Wells GA SB, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. xPublished 2009. Updated 03/11/2021. Accessed 03/11/2021.
  98. 98.↵
    Ferrario CM, Ahmad S, Groban L. Mechanisms by which angiotensin-receptor blockers increase ACE2 levels. Nat Rev Cardiol. 2020;17(6):378.
    OpenUrl
  99. 99.↵
    Guo X, Zhu Y, Hong Y. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis. Hypertension. 2020;76(2):e13–e14.
    OpenUrlCrossRefPubMed
  100. 100.
    Ssentongo AE, Ssentongo P, Heilbrunn ES, et al. Renin–angiotensin–aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis. Open Heart. 2020;7(2):e001353.
    OpenUrlAbstract/FREE Full Text
  101. 101.↵
    Lee MMY, Docherty KF, Sattar N, et al. Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes fromCoViD-19: systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2020.
  102. 102.↵
    Walkey AJ, Kumar VK, Harhay MO, et al. The Viral Infection and Respiratory Illness Universal Study (VIRUS): An International Registry of Coronavirus 2019-Related Critical Illness. Crit Care Explor. 2020;2(4):e0113.
    OpenUrl
  103. 103.
    Domecq JP, Lal A, Sheldrick CR, et al. Outcomes of Patients With Coronavirus Disease 2019 Receiving Organ Support Therapies: The International Viral Infection and Respiratory Illness Universal Study Registry. Crit Care Med. 2021.
  104. 104.
    Turek JR, Bansal V, Tekin A, et al. Rapid Project Management in a Time of COVID-19 Crisis: Lessons learned from a Global VIRUS: COVID-19 Registry. JMIR Preprints. 2021.
  105. 105.↵
    Walkey AJ, Sheldrick RC, Kashyap R, et al. Guiding Principles for the Conduct of Observational Critical Care Research for Coronavirus Disease 2019 Pandemics and Beyond: The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study Registry. Crit Care Med. 2020;48(11):e1038–e1044.
    OpenUrl
  106. 106.↵
    International Society of Hypertension. A statement from the International Society of Hypertension on COVID-19. https://ish-world.com/news/a/A-statement-from-the-International-Society-of-Hypertension-on-COVID-19/. xPublished 2020. Updated 03/11/2021. Accessed 03/11/2021.
  107. 107.↵
    Statement from the American Heart Association, Heart Failure Society of America, American College of Cardiology. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. Heart Fail Soc Am. 2020.
Back to top
Posted March 24, 2021.
Download PDF
Data/Code
Email
Mortality and Severity in COVID-19 Patients on ACEIs & ARBs - A Meta-Regression Analysis
Romil Singh, Sawai Singh Rathore, Hira Khan, Abhishek Bhurwal, Mack Sheraton, Prithwish Ghosh, Sohini Anand, Janaki Makadia, FNU Ayesha, Kiran S. Mahapure, Ishita Mehra, Aysun Tekin, Rahul Kashyap, Vikas Bansal
medRxiv 2021.03.14.21253557; doi: https://doi.org/10.1101/2021.03.14.21253557
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area